On the public citation graph
Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
0 signed · 154 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ijc.27632openalex-snapshot
Targeted therapy for triple‐negative breast cancer: Where are we?
inferredcites →https://doi.org/10.1002/jcb.25490openalex-snapshot
The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase‐Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple‐Negative Breast Cancer Cells
inferredcites →https://doi.org/10.1007/s10549-010-0851-xopenalex-snapshot
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
inferredcites →https://doi.org/10.1007/s10585-008-9169-zopenalex-snapshot
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity
inferredcites →https://doi.org/10.1007/s13277-015-4524-6openalex-snapshot
Anticancer effects of tributyltin chloride and triphenyltin chloride in human breast cancer cell lines MCF-7 and MDA-MB-231
inferredcites →https://doi.org/10.1016/0022-1759(92)90122-aopenalex-snapshot
An immunochemical analysis of the human nuclear phosphoprotein p53
inferredcites →https://doi.org/10.1016/j.cbi.2015.11.013openalex-snapshot
SZC015, a synthetic oleanolic acid derivative, induces both apoptosis and autophagy in MCF-7 breast cancer cells
inferredcites →https://doi.org/10.1016/j.ctrv.2014.10.004openalex-snapshot
p53 as a target for the treatment of cancer
inferredcites →https://doi.org/10.1016/j.hoc.2013.05.003openalex-snapshot
The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1016/j.tips.2010.11.004openalex-snapshot
Reactivation of p53: from peptides to small molecules
inferredcites →https://doi.org/10.1016/s1046-2023(03)00032-xopenalex-snapshot
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
inferredcites →https://doi.org/10.1038/81343openalex-snapshot
Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation
inferredcites →https://doi.org/10.1038/cddis.2013.417openalex-snapshot
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
inferredcites →https://doi.org/10.1038/cddis.2015.143openalex-snapshot
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
inferredcites →https://doi.org/10.1038/nature10933openalex-snapshot
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
inferredcites →https://doi.org/10.1038/nature11412openalex-snapshot
Comprehensive molecular portraits of human breast tumours
inferredcites →https://doi.org/10.1038/nm0302-282openalex-snapshot
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
inferredcites →https://doi.org/10.1038/onc.2009.425openalex-snapshot
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
inferredcites →https://doi.org/10.1038/sj.onc.1208419openalex-snapshot
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
inferredcites →https://doi.org/10.1042/bsr20140031openalex-snapshot
Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells
inferredcites →https://doi.org/10.1073/pnas.1416318112openalex-snapshot
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4
inferredcites →https://doi.org/10.1083/jcb.201009059openalex-snapshot
p53 and its mutants in tumor cell migration and invasion
inferredcites →https://doi.org/10.1093/annonc/mds279openalex-snapshot
ADAM-17: a novel therapeutic target for triple negative breast cancer
inferredcites →https://doi.org/10.1093/annonc/mdt384openalex-snapshot
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
inferredcites →https://doi.org/10.1093/carcin/23.12.2011openalex-snapshot
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
inferredcites →https://doi.org/10.1093/carcin/bgu160openalex-snapshot
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53
inferredcites →https://doi.org/10.1136/gutjnl-2015-309770openalex-snapshot
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
inferredcites →https://doi.org/10.1155/2015/139349openalex-snapshot
Synergistic Apoptotic Effect of Crocin and Paclitaxel or Crocin and Radiation on MCF-7 Cells, a Type of Breast Cancer Cell Line
inferredcites →https://doi.org/10.1158/0008-5472.can-04-1082openalex-snapshot
Apoptosis Resistance of MCF-7 Breast Carcinoma Cells to Ionizing Radiation Is Independent of p53 and Cell Cycle Control but Caused by the Lack of Caspase-3 and a Caffeine-Inhibitable Event
inferredcites →https://doi.org/10.1158/0008-5472.can-09-1947openalex-snapshot
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
inferredcites →https://doi.org/10.1158/0008-5472.can-11-0459openalex-snapshot
Multiple Stress Signals Activate Mutant p53 In Vivo
inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-3168openalex-snapshot
PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-1973openalex-snapshot
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2890openalex-snapshot
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0583openalex-snapshot
New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
inferredcites →https://doi.org/10.1172/jci45014openalex-snapshot
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
inferredcites →https://doi.org/10.1182/blood-2014-01-548800openalex-snapshot
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
inferredcites →https://doi.org/10.1200/jco.2011.40.7783openalex-snapshot
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
inferredcites →https://doi.org/10.1371/journal.pone.0130393openalex-snapshot
Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
inferredcites →https://doi.org/10.2144/000113083openalex-snapshot
TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays
inferredcites →https://doi.org/10.3892/ijo.31.4.777openalex-snapshot
Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells
inferredcites →https://doi.org/10.3892/ijo_00000416openalex-snapshot
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein
inferredcites →https://doi.org/10.4137/bcbcr.s32787openalex-snapshot
Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/cam4.7472openalex-snapshot
Emerging roles of tripartite motif family proteins ( TRIMs ) in breast cancer
inferred← citeshttps://doi.org/10.1002/ijc.33197openalex-snapshot
Drugging “undruggable” genes for cancer treatment: Are we making progress?
inferred← citeshttps://doi.org/10.1007/978-1-0716-0247-8_25openalex-snapshot
High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-1-0716-4901-5_30openalex-snapshot
High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-981-10-7506-3_17openalex-snapshot
Impact of Genomics on Personalization of Breast Cancer Care
inferred← citeshttps://doi.org/10.1007/s10549-018-4753-7openalex-snapshot
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
inferred← citeshttps://doi.org/10.1007/s10549-019-05435-1openalex-snapshot
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
inferred← citeshttps://doi.org/10.1007/s10549-022-06673-6openalex-snapshot
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
inferred← citeshttps://doi.org/10.1007/s10549-023-07107-7openalex-snapshot
Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach
inferred← citeshttps://doi.org/10.1007/s10637-020-01018-wopenalex-snapshot
The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells
inferred← citeshttps://doi.org/10.1007/s10637-024-01504-5openalex-snapshot
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630
inferred← citeshttps://doi.org/10.1007/s10787-022-01094-9openalex-snapshot
Anti-inflammatory effects of PRIMA-1MET (mutant p53 reactivator) induced by inhibition of nuclear factor-κB on rheumatoid arthritis fibroblast-like synoviocytes
inferred← citeshttps://doi.org/10.1007/s12013-024-01322-9openalex-snapshot
miR‐449a: A Promising Biomarker and Therapeutic Target in Cancer and Other Diseases
inferred← citeshttps://doi.org/10.1007/s12032-022-01733-9openalex-snapshot
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells
inferred← citeshttps://doi.org/10.1007/s12032-024-02469-4openalex-snapshot
Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review
inferred← citeshttps://doi.org/10.1007/s12609-025-00618-wopenalex-snapshot
p53 Targeted Therapies in Triple Negative Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12668-022-00991-1openalex-snapshot
Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies
inferred← citeshttps://doi.org/10.1007/s12672-025-04366-2openalex-snapshot
The role of PCMT1 in prognosis tumor immune microenvironment and therapeutic responses across cancers
inferred← citeshttps://doi.org/10.1007/s12672-026-04622-zopenalex-snapshot
Comprehensive prognostic and immune infiltration assessment of LGALS3BP in pan-cancer patients
inferred← citeshttps://doi.org/10.1016/b978-0-12-824152-3.00004-4openalex-snapshot
The involvement of human papillomavirus in breast cancer in general and the different prognostic biomarkers in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2018.05.019openalex-snapshot
Targeting forkhead box M1 transcription factor in breast cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2024.116047openalex-snapshot
TP53R175H mutation promotes breast cancer cell proliferation through CORO1A–P38 MAPK pathway regulation
inferred← citeshttps://doi.org/10.1016/j.bulcan.2026.04.016openalex-snapshot
Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies
inferred← citeshttps://doi.org/10.1016/j.canlet.2017.09.053openalex-snapshot
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
inferred← citeshttps://doi.org/10.1016/j.canlet.2024.217008openalex-snapshot
Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.102855openalex-snapshot
Triple negative breast cancer: A thorough review of biomarkers
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.02.012openalex-snapshot
Anticancer activity of palladium-based complexes against triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.06.023openalex-snapshot
Mutant p53 as a target for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.06.033openalex-snapshot
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
inferred← citeshttps://doi.org/10.1016/j.ejmech.2020.112812openalex-snapshot
Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.gene.2018.05.025openalex-snapshot
Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e26260openalex-snapshot
Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
inferred← citeshttps://doi.org/10.1016/j.premed.2026.100032openalex-snapshot
Advances in cancer biomarkers: Diagnostic, prognostic, and therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.07.005openalex-snapshot
Targeting p53 for the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.tiv.2024.105846openalex-snapshot
Comprehensive studies on the biological activities of human metastatic (MDA-MB-231) and non-metastatic (MCF-7) breast cancer cell lines, directly or combinedly treated using non-thermal plasma-based approaches
inferred← citeshttps://doi.org/10.1016/j.tranon.2018.08.009openalex-snapshot
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
inferred← citeshttps://doi.org/10.1016/j.tranon.2024.102025openalex-snapshot
Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer
inferred← citeshttps://doi.org/10.1038/nrc.2017.109openalex-snapshot
Targeting mutant p53 for efficient cancer therapy
inferred← citeshttps://doi.org/10.1038/s41417-026-01026-7openalex-snapshot
Identification of ribosomal protein eL21 as a novel externalized protein and a target in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1038/s41419-023-05740-0openalex-snapshot
Necrocide 1 mediates necrotic cell death and immunogenic response in human cancer cells
inferred← citeshttps://doi.org/10.1038/s41467-021-27142-6openalex-snapshot
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)
inferred← citeshttps://doi.org/10.1038/s41598-019-50141-zopenalex-snapshot
Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells
inferred← citeshttps://doi.org/10.1038/s41698-022-00303-6openalex-snapshot
Impact of TP53 mutations in Triple Negative Breast Cancer
inferred← citeshttps://doi.org/10.1074/jbc.ra118.004671openalex-snapshot
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
inferred← citeshttps://doi.org/10.1080/13543784.2022.2159805openalex-snapshot
‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’
inferred← citeshttps://doi.org/10.1080/14728222.2017.1297798openalex-snapshot
Tp53 and its potential therapeutic role as a target in bladder cancer
inferred← citeshttps://doi.org/10.1080/14737140.2021.1840984openalex-snapshot
Triple-negative breast cancer: promising prognostic biomarkers currently in development
inferred← citeshttps://doi.org/10.1080/15384101.2019.1638192openalex-snapshot
Inflammatory signaling in genomically instable cancers
inferred← citeshttps://doi.org/10.1088/2057-1976/aaf2c3openalex-snapshot
Viability and cell cycle studies of metastatic triple negative breast cancer cells using low voltage electrical pulses and herbal curcumin
inferred← citeshttps://doi.org/10.1093/rpsppr/rqaf014openalex-snapshot
Lysosome-mediated cytotoxicity in breast cancer subtype cells treated with doxorubicin
inferred← citeshttps://doi.org/10.1097/js9.0000000000001799openalex-snapshot
Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis
inferred← citeshttps://doi.org/10.1097/md.0000000000015449openalex-snapshot
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
inferred← citeshttps://doi.org/10.1101/2022.12.27.522044openalex-snapshot
Alternative Polyadenylation alters UBASH3B-ZNF652 competition to involve in Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.1111/jcmm.17465openalex-snapshot
Potential of chimeric antigen receptor ( CAR )‐redirected immune cells in breast cancer therapies: Recent advances
inferred← citeshttps://doi.org/10.1139/cjpp-2023-0031openalex-snapshot
PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis
inferred← citeshttps://doi.org/10.1172/jci.insight.138382openalex-snapshot
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
inferred← citeshttps://doi.org/10.1186/s12885-019-5394-xopenalex-snapshot
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
inferred← citeshttps://doi.org/10.1186/s12885-019-5407-9openalex-snapshot
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
inferred← citeshttps://doi.org/10.1186/s13045-019-0725-6openalex-snapshot
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
inferred← citeshttps://doi.org/10.1186/s13045-022-01260-0openalex-snapshot
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies
inferred← citeshttps://doi.org/10.1186/s13045-022-01341-0openalex-snapshot
Recent advances in therapeutic strategies for triple-negative breast cancer
inferred← citeshttps://doi.org/10.1186/s13046-019-1066-6openalex-snapshot
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
inferred← citeshttps://doi.org/10.1186/s40364-024-00676-9openalex-snapshot
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy
inferred← citeshttps://doi.org/10.1200/po.17.00245openalex-snapshot
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.12677/acm.2021.1111807openalex-snapshot
Research Progress of Mutant p53 as a Potential Therapeutic Target for Breast Cancer
inferred← citeshttps://doi.org/10.13023/etd.2020.329openalex-snapshot
Examining the Role of Metabolic Pathways as Therapeutic Modalities for Triple Negative Breast Cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0198525openalex-snapshot
Exploring novel key regulators in breast cancer network
inferred← citeshttps://doi.org/10.14264/662cbf8openalex-snapshot
Investigating molecular targets of the DNA damage response in triple negative breast cancer
inferred← citeshttps://doi.org/10.14735/amko20182s71openalex-snapshot
Prima-1 and APR-246 in Cancer Therapy
inferred← citeshttps://doi.org/10.15761/crr.1000205openalex-snapshot
Combined treatment with p53-activating drug APR-246 and a phosphatidylserine-targeting antibody, 2aG4, inhibits growth of human triple-negative breast cancer xenografts
inferred← citeshttps://doi.org/10.18231/j.jdpo.2022.054openalex-snapshot
Survivin and p53 expression in benign and malignant lesions of breast
inferred← citeshttps://doi.org/10.18632/oncotarget.26177openalex-snapshot
Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling
inferred← citeshttps://doi.org/10.18632/oncotarget.27430openalex-snapshot
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
inferred← citeshttps://doi.org/10.21037/atm-20-3773openalex-snapshot
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer
inferred← citeshttps://doi.org/10.21037/cco-20-138openalex-snapshot
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors—proceedings from breast cancer expert group meeting
inferred← citeshttps://doi.org/10.21037/tbcr-20-66openalex-snapshot
The evolution and advances of biomarker use in clinical trials for breast cancer treatment—a narrative review
inferred← citeshttps://doi.org/10.21037/tbcr-22-22openalex-snapshot
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2090541/v1openalex-snapshot
Necrocide 1 Mediates a Non-Apoptotic Necrotic Cell Death and Immunogenic Response in Human Cancer Cells
inferred← citeshttps://doi.org/10.21248/gups.82540openalex-snapshot
Mutationsanalyse bei PatientInnen mit metastasiertem Mammakarzinom
inferred← citeshttps://doi.org/10.2147/bctt.s208706openalex-snapshot
APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice
inferred← citeshttps://doi.org/10.21873/anticanres.12041openalex-snapshot
New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsNew Drug Combination Strategies in Melanoma: Current Status and Future Directions
inferred← citeshttps://doi.org/10.2217/bmm-2016-0169openalex-snapshot
Elevated Expression of Thyroid Hormone Receptor-Interacting Protein 13 Drives Tumorigenesis and Affects Clinical Outcome
inferred← citeshttps://doi.org/10.2217/pgs-2017-0117openalex-snapshot
Triple-Negative Breast Cancer and the Potential for Targeted Therapy
inferred← citeshttps://doi.org/10.26420/austinjnutrifoodsci.2017.1090openalex-snapshot
The Pharmacological Effect of Omega-3 Fatty Acids Prevent Cancer Progression in Colon and Breast Cancer
inferred← citeshttps://doi.org/10.3324/haematol.2018.199364openalex-snapshot
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.3389/fgene.2022.843579openalex-snapshot
A Comprehensive Pan-Cancer Analysis for Pituitary Tumor-Transforming Gene 1
inferred← citeshttps://doi.org/10.3389/fgene.2022.927046openalex-snapshot
A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2)
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1038225openalex-snapshot
Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer
inferred← citeshttps://doi.org/10.3389/fonc.2021.664848openalex-snapshot
Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
inferred← citeshttps://doi.org/10.3390/biomedicines10112843openalex-snapshot
Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
inferred← citeshttps://doi.org/10.3390/biomedicines14010178openalex-snapshot
Mutational Landscape Analysis of BRCA1/2 and Identification of Extracellular-Vesicle-Related Biomarkers in Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers13153920openalex-snapshot
Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer
inferred← citeshttps://doi.org/10.3390/cancers14184499openalex-snapshot
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
inferred← citeshttps://doi.org/10.3390/cancers15143560openalex-snapshot
The Development of p53-Targeted Therapies for Human Cancers
inferred← citeshttps://doi.org/10.3390/cancers9120172openalex-snapshot
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
inferred← citeshttps://doi.org/10.3390/ijms22083855openalex-snapshot
The Influence of Cold Atmospheric Pressure Plasma-Treated Media on the Cell Viability, Motility, and Induction of Apoptosis in Human Non-Metastatic (MCF7) and Metastatic (MDA-MB-231) Breast Cancer Cell Lines
inferred← citeshttps://doi.org/10.3390/molecules23061479openalex-snapshot
Targeting Transcription Factors for Cancer Treatment
inferred← citeshttps://doi.org/10.3390/molecules26216388openalex-snapshot
In Vitro Effects of Papaverine on Cell Proliferation, Reactive Oxygen Species, and Cell Cycle Progression in Cancer Cells
inferred← citeshttps://doi.org/10.3390/ph14020169openalex-snapshot
Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer
inferred← citeshttps://doi.org/10.3892/etm.2021.10452openalex-snapshot
MicroRNA‑449a inhibits cell proliferation and migration by regulating mutant p53 in MDA‑MB‑468 cells
inferred← citeshttps://doi.org/10.3892/ijo.2025.5758openalex-snapshot
Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)
inferred← citeshttps://doi.org/10.3892/ol.2017.6641openalex-snapshot
Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer
inferred← citeshttps://doi.org/10.3892/ol.2019.10940openalex-snapshot
Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma
inferred← citeshttps://doi.org/10.3892/ol.2019.9984openalex-snapshot
Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico
inferred← citeshttps://doi.org/10.51253/pafmj.v71isuppl-1.3073openalex-snapshot
IMMUNOHISTOCHEMICAL EXPRESSION OF P53 IN INVASIVE DUCTAL CARCINOMA OF BREAST IN PAKISTANI WOMEN
inferred← citeshttps://doi.org/10.62051/q0djfh23openalex-snapshot
p53 Correlation with Triple-negative Breast Cancer and Potential Treatments
inferred← citeshttps://doi.org/10.70675/3981c82bzf3baz4b17zaa7eza762575e0b9dopenalex-snapshot
Effet de l’inactivation du gène suppresseur de tumeur p53 et de sa réactivation pharmacologique sur la réponse cytotoxique anti-tumorale
inferred← citeshttps://doi.org/10.7150/thno.81847openalex-snapshot
Role of p53 in breast cancer progression: An insight into p53 targeted therapy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.